NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Tuesday that its second quarter revenues increased 3 percent year over year, with growth posted for both its life sciences products and clinical lab services.

The New York-based diagnostics firm brought in total revenues of $22.9 million for the three months ended Jan. 31, up from $22.2 million for the second quarter of 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.